Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US~OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country
Mumbai, 19 May 2022 (GNI): Regrow Biosciences, an Indian-centric global biotech company, is glad to announce a breakthrough achievement of getting a USFDA nod for conducting a phase II trial of its lead product ‘OSSGROW,’…